Elanco Receives USDA Approval for Befrena, New Canine Dermatitis Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 01 2026
0mins
Should l Buy ELAN?
Source: NASDAQ.COM
- New Drug Approval: Elanco Animal Health announced that its new anti-IL31 monoclonal antibody injection, Befrena, has received USDA approval and is expected to launch in the first half of 2026, further solidifying its position in the veterinary dermatology market.
- Dosing Interval Advantage: Befrena offers a dosing interval of 6 to 8 weeks, providing a longer treatment window compared to the market competitor lokivetmab, which is administered every 4 to 8 weeks, potentially attracting more veterinarians and pet owners.
- Product Line Expansion: This approval marks Elanco's second dermatology product clearance in less than 18 months, with Befrena joining Zenrelia, a once-daily oral JAK inhibitor that effectively controls skin allergies, enhancing the company's product portfolio.
- Market Reaction: Despite the new drug approval, Elanco's stock closed at $22.63 on December 31, down 0.57% from the previous session, indicating that market response to the new product still requires observation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELAN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELAN
Wall Street analysts forecast ELAN stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.790
Low
22.00
Averages
25.50
High
30.00
Current: 24.790
Low
22.00
Averages
25.50
High
30.00
About ELAN
Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Black Creek Investment Management Acquires Eagle Materials Shares
- New Investment Position: Black Creek Investment Management established a new position in Eagle Materials by acquiring 502,120 shares in Q4 2025, with an estimated trade value of $103.78 million, indicating confidence in the construction materials sector amid a potential infrastructure spending rebound.
- Asset Allocation Significance: This new position accounts for 5.1% of Black Creek's reportable assets in its 13F filing, ranking among its top five holdings, which underscores the firm's strategic focus on this stock.
- Strong Financial Performance: Eagle Materials reported $556 million in quarterly revenue and $3.22 in diluted EPS for its latest fiscal quarter, with cement volumes rising 9% year-over-year, demonstrating resilience despite softness in the residential market.
- Share Buyback Strategy: The company repurchased approximately 648,000 shares for $142.6 million in the quarter, reinforcing consistent capital allocation and reflecting management's confidence in future growth prospects.
See More
Elanco Animal Health Board Members Not Seeking Reelection
- Board Changes: Elanco Animal Health announced that two board members, R. David Hoover and Deborah Kochevar, will not seek reelection after the 2026 annual shareholder meeting, reducing the board size to nine members, indicating a shift in corporate governance structure.
- Historical Context: Hoover has served as the first chairman since the company's IPO in September 2018, while Kochevar joined in March 2019 during Elanco's spinoff from Eli Lilly, and their departures signify a new phase in the company's governance.
- Future Implications: The change in board members may impact the company's strategic direction and decision-making processes, necessitating that Elanco ensures new members bring fresh perspectives and expertise to support long-term growth objectives.
- Market Reaction: Although this transition has not triggered significant market volatility, investors will closely monitor the appointment of new directors and their potential influence on the company's future strategy to maintain a competitive edge in the animal health market.
See More
Elanco Animal Health Board Updates Leadership
- Board Changes: Elanco Animal Health announced that R. David Hoover and Deborah Kochevar will not seek re-election at the 2026 Annual Meeting, with Hoover serving as the first Chairman since the company's IPO in 2018 and Kochevar joining in 2019, both having made significant contributions to the company's development.
- Hoover's Legacy: Hoover provided critical strategic guidance during the company's early independence, helping Elanco establish a robust governance framework and clear strategic direction, which laid the foundation for sustainable growth, as expressed by Chairman Kurzius.
- Kochevar's Contributions: Under Kochevar's leadership of the Innovation, Science, and Technology committee, the company advanced its innovation pipeline, with both Chairman Kurzius and CEO Simmons acknowledging her veterinary expertise as vital for the company's future development.
- Board Structure Adjustment: Following these changes, Elanco's Board will consist of nine directors, reflecting the company's strong prospects for continued growth and long-term value creation, ensuring its leadership position in the animal health sector.
See More
Elanco Animal Health Board Updates Leadership
- Board Changes: Elanco Animal Health announced that R. David Hoover and Deborah Kochevar will not seek re-election at the 2026 Annual Meeting, marking a significant shift in the company's governance structure that could impact future strategic directions.
- Founding Chairman Retirement: Hoover, who has served as Chairman since the company's IPO in 2018, is credited with being a foundational leader for Elanco's success as an independent entity, leaving future leadership to navigate the challenges of sustainable growth.
- Innovation Committee Leadership: Kochevar's tenure on the board, particularly her leadership of the Innovation, Science, and Technology committee, was crucial in establishing the company's innovation pipeline, and the new board will need to maintain this culture of scientific excellence moving forward.
- Board Structure Adjustment: Following the departure of these two directors, Elanco's board will consist of nine members, a change that may affect the company's decision-making efficiency and strategic execution capabilities.
See More
ELANCO PROVIDES BOARD OF DIRECTORS UPDATE
- Announcement of Updates: RPT Elanco has announced updates regarding its Board of Directors.
- Board Composition Changes: The updates may include changes in the composition or roles within the Board of Directors.
See More
ELANCO ANIMAL HEALTH INC - DAVID HOOVER RETIRES FROM ELANCO BOARD (NOT AS 'CHAIRMAN')
- Retirement Announcement: David Hoover has announced his retirement from the Elanco Animal Health board.
- Clarification on Role: It is specified that he is retiring as a member, not as the chairman of the board.
See More
Black Creek Investment Management Acquires Eagle Materials Shares
- New Investment Position: Black Creek Investment Management established a new position in Eagle Materials by acquiring 502,120 shares in Q4 2025, with an estimated trade value of $103.78 million, indicating confidence in the construction materials sector amid a potential infrastructure spending rebound.
- Asset Allocation Significance: This new position accounts for 5.1% of Black Creek's reportable assets in its 13F filing, ranking among its top five holdings, which underscores the firm's strategic focus on this stock.
- Strong Financial Performance: Eagle Materials reported $556 million in quarterly revenue and $3.22 in diluted EPS for its latest fiscal quarter, with cement volumes rising 9% year-over-year, demonstrating resilience despite softness in the residential market.
- Share Buyback Strategy: The company repurchased approximately 648,000 shares for $142.6 million in the quarter, reinforcing consistent capital allocation and reflecting management's confidence in future growth prospects.
See More
Elanco Animal Health Board Members Not Seeking Reelection
- Board Changes: Elanco Animal Health announced that two board members, R. David Hoover and Deborah Kochevar, will not seek reelection after the 2026 annual shareholder meeting, reducing the board size to nine members, indicating a shift in corporate governance structure.
- Historical Context: Hoover has served as the first chairman since the company's IPO in September 2018, while Kochevar joined in March 2019 during Elanco's spinoff from Eli Lilly, and their departures signify a new phase in the company's governance.
- Future Implications: The change in board members may impact the company's strategic direction and decision-making processes, necessitating that Elanco ensures new members bring fresh perspectives and expertise to support long-term growth objectives.
- Market Reaction: Although this transition has not triggered significant market volatility, investors will closely monitor the appointment of new directors and their potential influence on the company's future strategy to maintain a competitive edge in the animal health market.
See More
Elanco Animal Health Board Updates Leadership
- Board Changes: Elanco Animal Health announced that R. David Hoover and Deborah Kochevar will not seek re-election at the 2026 Annual Meeting, with Hoover serving as the first Chairman since the company's IPO in 2018 and Kochevar joining in 2019, both having made significant contributions to the company's development.
- Hoover's Legacy: Hoover provided critical strategic guidance during the company's early independence, helping Elanco establish a robust governance framework and clear strategic direction, which laid the foundation for sustainable growth, as expressed by Chairman Kurzius.
- Kochevar's Contributions: Under Kochevar's leadership of the Innovation, Science, and Technology committee, the company advanced its innovation pipeline, with both Chairman Kurzius and CEO Simmons acknowledging her veterinary expertise as vital for the company's future development.
- Board Structure Adjustment: Following these changes, Elanco's Board will consist of nine directors, reflecting the company's strong prospects for continued growth and long-term value creation, ensuring its leadership position in the animal health sector.
See More
Elanco Animal Health Board Updates Leadership
- Board Changes: Elanco Animal Health announced that R. David Hoover and Deborah Kochevar will not seek re-election at the 2026 Annual Meeting, marking a significant shift in the company's governance structure that could impact future strategic directions.
- Founding Chairman Retirement: Hoover, who has served as Chairman since the company's IPO in 2018, is credited with being a foundational leader for Elanco's success as an independent entity, leaving future leadership to navigate the challenges of sustainable growth.
- Innovation Committee Leadership: Kochevar's tenure on the board, particularly her leadership of the Innovation, Science, and Technology committee, was crucial in establishing the company's innovation pipeline, and the new board will need to maintain this culture of scientific excellence moving forward.
- Board Structure Adjustment: Following the departure of these two directors, Elanco's board will consist of nine members, a change that may affect the company's decision-making efficiency and strategic execution capabilities.
See More
ELANCO PROVIDES BOARD OF DIRECTORS UPDATE
- Announcement of Updates: RPT Elanco has announced updates regarding its Board of Directors.
- Board Composition Changes: The updates may include changes in the composition or roles within the Board of Directors.
See More
ELANCO ANIMAL HEALTH INC - DAVID HOOVER RETIRES FROM ELANCO BOARD (NOT AS 'CHAIRMAN')
- Retirement Announcement: David Hoover has announced his retirement from the Elanco Animal Health board.
- Clarification on Role: It is specified that he is retiring as a member, not as the chairman of the board.
See More
